Venture Capital

A Chinese city is investing in a new tourism model, blending adrenaline sports and ancient culture to capture a lucrative youth market. A strategic play.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

With backing from the US and Australia, a titanium giant is pivoting to critical minerals, a strategic move challenging global supply chain dominance.

Reborn Coffee touts a tech-driven global expansion, but a looming Nasdaq delisting and deep financial losses paint a much more complicated picture.

A landmark deal for two Airbus A321neos signals more than fleet expansion; it's a strategic play to turn Tashkent into the next major East-West air hub.

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

A $48M investment creates 67 homes for Montréal women, but its real impact is a new collaborative model that treats housing as essential healthcare.

An unsolicited bid from Paramount Skydance challenges Netflix's deal for WBD, sparking a high-stakes war for Hollywood's most iconic content library.

Prospect Enhanced Yield Fund's debut 9% distribution tempts income seekers, but a look into the structured credit market reveals a complex risk-reward.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

As the humanoid robotics market soars towards $7.7B, one firm is recruiting top talent to find the next big winner. What does this move signal to investors?

A new investment narrative targets 'essential' sectors. A deep dive reveals a complex mix of real strategy, verifiable progress, and pure promotion.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

A junior miner's savvy strategy to re-examine old drill core could unlock new value, positioning its gold-lithium project at the nexus of today's markets.

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.